bexarotene has been researched along with Dermatoses in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zic, JA | 1 |
| Busam, K; Geller, S; Hamlin, PA; Horwitz, SM; Moskowitz, AJ; Myskowski, PL | 1 |
| Gunia-Krzyżak, A; Marona, H; Słoczyńska, K; Waszkielewicz, AM; Żelaszczyk, D | 1 |
| Bair, SM; Cherpelis, BS; Fenske, NA; Glass, LF; Marquez, CB; Smithberger, EE; Wenham, RM | 1 |
1 review(s) available for bexarotene and Dermatoses
| Article | Year |
|---|---|
Diagnosis and Management of Cutaneous Lymphomas Including Cutaneous T-cell Lymphoma.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Agents, Immunological; Arthropods; Bexarotene; Bites and Stings; Brentuximab Vedotin; Diagnosis, Differential; Humans; Hyperlipidemias; Hypothyroidism; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Lymphoma, T-Cell, Cutaneous; Lymphomatoid Papulosis; Mycosis Fungoides; Peripheral Nervous System Diseases; Prognosis; Sezary Syndrome; Skin Diseases; Skin Neoplasms | 2021 |
3 other study(ies) available for bexarotene and Dermatoses
| Article | Year |
|---|---|
Treatment of Rosai-Dorfman disease with oral bexarotene: a case series.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Bexarotene; Female; Histiocytosis, Sinus; Humans; Male; Middle Aged; Retrospective Studies; Skin Diseases; Treatment Outcome | 2019 |
Skin metabolism established with the use of MetaSite for selected retinoids employed in topical and systemic treatment of various skin disorders and found in cosmeceuticals.
Topics: Acitretin; Adapalene; Administration, Topical; Bexarotene; Cosmeceuticals; Cytochrome P-450 Enzyme System; Humans; Hydroxylation; Inactivation, Metabolic; Retinoids; Skin; Skin Diseases; Software; Structure-Activity Relationship; Tetrahydronaphthalenes; Vitamin A | 2015 |
Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene.
Topics: Adenocarcinoma, Papillary; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bexarotene; Carboplatin; Clinical Trials as Topic; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Female; Humans; Hypertriglyceridemia; Hypothyroidism; Keratoacanthoma; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Paclitaxel; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Tetrahydronaphthalenes | 2009 |